Mineralys Therapeutics Inc (MLYS) Files Form 424B5 on June 3

Mineralys Therapeutics Inc (MLYS) submitted Form 424B5 on June 3, detailing information regarding their securities offering. This filing is typically a prospectus supplement, which may impact investor interest and liquidity in the stock. Disclosure of this nature is often crucial in maintaining transparency with potential investors and regulatory bodies. The filing might influence market perception of the company's financial activities and future prospects.